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The presence of SARS-CoV-2 gastrointestinal infection has recently been reported by two 
independent groups from China 1, 2. Also, liver injury -in part presumably explained by viral 
infection of liver cells may be present in about 60% of the infected patients 3. Therefore, 
patients with chronic liver disease may be vulnerable to the serious clinical consequences of 
COVID-19 infection. Likewise, emerging clinical data suggest that males with comorbidities, 
including obesity, are more likely to present sever disease 4, 5. While the biological 
mechanisms behind this observation are unclear, it has been speculated that sex-based 
immunological and or/ hormonal differences may account in part for that.  
There is evidence highlighting angiotensin-converting enzyme 2 (ACE2) as one of the host 
receptors for cell entry of members of the SARS-CoV group, including SARS-CoV-2 6.
Structural analysis showed several binding motifs between the SARS-CoV spike protein 
receptor-binding domain and human ACE2 6. Besides its role in catalyzing the cleavage of 
angiotensin I into angiotensin 1-9, and angiotensin II i to the vasodilator angiotensin 1-7, 
ACE2 is involved in cellular pathways associated with other viral entry into host cells.  
Gene expression levels of ACE2 differ across human body . The highest expression levels are 
in the small intestine and terminal ileum, and ACE2 expression levels in the liver and lung are 
much lower than that of the gastrointestinal tract. One remarkable aspect of the ACE2 is that 
the gene maps on the non-pseudoautosomal, that is, the X-specific, region of the chromosome 
X (Xp22.2). It is largely known that in order to balance the dosage effect of X-linked genes, 
one of the two X chromosomes is randomly inactivated in females during development; this 
process is called X inactivation.  Nevertheless, while most genes are silenced, about 15% of 
X-linked human genes escape from inactivation 7. More importantly, X-escape is not uniform 
across different tissues. In fact, it was shown that ~10% of gene escape occurs selectively in 
specific tissues 7. These molecular aspects are of medical importance be ause they could 
explain sex differences in the natural course of human diseases, including COVID-19. 
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A recent systematic survey of the landscape of human X-linked genes inactivation using 
RNA sequencing-based approaches showed that ACE2 presents remarkable differences in 
male–female expression levels 8. Tukiainen et al. suggested that tissue differences in X-
escape can directly translate into tissue-specific sex biases in gene expression 8. Specifically, 
the study showed not only that ACE2 is among the 82 X-escaping genes but also highlighted 
that there might be differences in the liver and lung ACE2 expression levels between males 
and females 8. Paradoxically, escape of ACE2 from X-inactivation resulted in low levels of 
expression in the liver, lung, and visceral adipose tissue of women 8. Conversely, ACE2 
expression levels in colon transverse and subcutaneous adipose tissue were significantly 
higher in females than males 8.   
Collectively, these novel observations may have important clinical implications for COVID-
19 infected patients. First, differences between meand women in liver ACE2 expression 
levels may help to explain potential clinical differences in the course of COVID-19 infection 
in patients with underlying chronic liver disease. S cond, differences between men and 
women in ACE2 expression levels in gastrointestinal tissues due to escaping from X-
inactivation, including colon, could result in different transmission patterns, including fecal-
oral transmission. Third, gender-linked diferential expression levels in adipose tissue and/or 
visceral fat, might also shed light into potential differences in the odds of presenting severe 
complications and in-hospital death associated withcomorbidities, including severe obesity.  
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